Literature DB >> 17714623

Influenza vaccine programs and pregnancy: new Canadian evidence for immunization.

Shelly A McNeil1, Linda Dodds, Victoria M Allen, Jeffrey Scott, Beth Halperin, Noni MacDonald.   

Abstract

Among healthy pregnant women, excess deaths due to influenza were documented during pandemics, but the impact of influenza on pregnant women in non-pandemic years is not clear. In Canada, influenza immunization is recommended for pregnant women only if they have comorbidities known to place them at increased risk of complications or if they deliver during influenza season, therefore becoming a contact of a high-risk infant. The National Advisory Committee on Immunization has indicated that additional evidence, relevant to healthy pregnant Canadian women, is needed to support a recommendation for influenza immunization for all pregnant women. In this commentary we summarize new Canadian data supporting universal influenza immunization for pregnant women and discuss ways in which the Society of Obstetricians and Gynaecologists of Canada might take a leadership role in making influenza vaccination in pregnancy a priority to decrease influenza morbidity in pregnant Canadian women.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17714623     DOI: 10.1016/s1701-2163(16)32556-7

Source DB:  PubMed          Journal:  J Obstet Gynaecol Can        ISSN: 1701-2163


  2 in total

1.  Release of the statement on influenza for the 2007 2008 season from the National Advisory Committee on Immunization.

Authors:  Joanne M Langley
Journal:  CMAJ       Date:  2007-10-23       Impact factor: 8.262

2.  Designs of two randomized, community-based trials to assess the impact of influenza immunization during pregnancy on respiratory illness among pregnant women and their infants and reproductive outcomes in rural Nepal.

Authors:  James M Tielsch; Mark Steinhoff; Joanne Katz; Janet A Englund; Jane Kuypers; Subarna K Khatry; Laxman Shrestha; Steven C LeClerq
Journal:  BMC Pregnancy Childbirth       Date:  2015-02-20       Impact factor: 3.007

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.